PLK1/BRD4-IN-3

• UNSPSC Description:

  PLK1/BRD4-IN-3 (Compound 21) is a selective dual inhibitor for bromodomain 4 (BRD4) and polo-like kinase 1 (PLK1). PLK1/BRD4-IN-3 inhibits BRD4-BD1, PLK1 and BRDT-BD1, with IC50s of 0.059, 0.127 and 0.245 μM, respectively[1].

• Target Antigen:

  Epigenetic Reader Domain; Polo-like Kinase (PLK)

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Epigenetics

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/plk1-brd4-in-3.html

• Solubility:

  DMSO : 16.67 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O=C1[C@H](C)N(C2CCCC2)C3=NC(NC4=CC=C(C(NC5CCN(C)CC5)=O)C=C4OC6CCCC6)=NC=C3N1C

• Molecular Weight:

  561.72

• References & Citations:

  [1]Liu S, et al., Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors. J Med Chem. 2018 Sep 13;61(17):7785-7795.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2251709-91-6